Articles from Omnicell, Inc.

Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the fourth quarter and full year 2024, before market open on Thursday, February 6, 2025. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day.

Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy care delivery model, announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 1:30 p.m. PT.

Omnicell, Inc. (Nasdaq:OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced OmniSphere, a next-generation, cloud native, software workflow engine and data platform. This groundbreaking new platform, designed to leverage the full power of a cloud native architecture, seamlessly integrates robotics and smart devices to support more secure, data-driven, medication management across the continuum of care.

Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy care delivery model, announced that it will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 2:00 p.m. ET.

Omnicell, Inc. (NASDAQOMCL) (“Omnicell”) today announced the pricing of $150.0 million aggregate principal amount of 1.00% Convertible Senior Notes due 2029 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Omnicell also granted the initial purchasers of the notes an option to purchase, during a 13-day period beginning on, and including, the first date on which the notes are issued, up to an additional $22.5 million aggregate principal amount of notes. The sale of the notes is expected to close on November 22, 2024, subject to customary closing conditions.

Omnicell, Inc. (NASDAQOMCL) (“Omnicell”) today announced that it intends to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of Convertible Senior Notes due 2029 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Omnicell also intends to grant the initial purchasers of the notes an option to purchase, during a 13-day period beginning on, and including, the first date on which the notes are issued, up to an additional $22.5 million aggregate principal amount of notes.

Omnicell, Inc. (NASDAQOMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced results for its third quarter ended September 30, 2024.

Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy care delivery model, will release its financial results for the third quarter 2024, before market open on Wednesday, October 30, 2024. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day.

Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced that Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of the Company, effective October 7, 2024.

Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy care delivery model, today announced Central Med Automation Service, a subscription-based solution designed to help health systems establish and continuously optimize centralized medication management for Consolidated Pharmacy Services Centers (CPSCs) and similar operations. Central Med Automation Service is intended to streamline medication dispensing from a central fulfillment area throughout the entire health system enterprise, which is expected to enhance inventory visibility, scalability, and patient safety.

Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy care delivery model, announced that it will present at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 1:30 p.m. ET.

EnlivenHealth, a division of Omnicell, Inc., is pleased to announce the release of a first-of-a-kind Scope of Practice and Reimbursement Snapshot solution for members of Good Neighbor Pharmacy, a national franchise for independent pharmacies offered through Cencora. This new resource is designed to empower Good Neighbor Pharmacy members by providing critical information on clinical services and reimbursement information tailored to each state.

Omnicell, Inc. (NASDAQOMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced results for its second quarter ended June 30, 2024.

Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy care delivery model, will release its financial results for the second quarter 2024, before market open on Thursday, August 1, 2024. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day.

Omnicell, Inc. (Nasdaq:OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced continued support for the global charity Mercy Ships with the donation of solutions from the recently announced XT Amplify program.

Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy care delivery model, will present at the BofA Securities 2024 Health Care Conference in Las Vegs, NV, on Wednesday, May 15, 2024 at 3:40 p.m. PT.

Omnicell, Inc. (NASDAQOMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced results for its first quarter ended March 31, 2024.

Omnicell, Inc. (Nasdaq:OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced XT Amplify, a multi-year innovation program that is intended to maximize value for hospitals, health systems, and post-acute care facilities that have invested in Omnicell’s XT Automated Dispensing System while also seeking to drive enhanced clinical and operational outcomes at the points of care and within pharmacies.

Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy care delivery model, will release its financial results for the first quarter 2024, before market open on Thursday, May 2, 2024. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day.

Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy care delivery model, will present at the virtual KeyBanc Annual Life Sciences & MedTech Investor Forum on Wednesday, March 20, 2024 at 4:30 p.m. ET.

Omnicell, Inc. (NASDAQOMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced results for its fiscal year and fourth quarter ended December 31, 2023.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the fourth quarter and full year 2023, before market open on Thursday, February 8, 2024. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day.

Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced that the Board of Directors elected Eileen Voynick to the Board, effective January 5, 2024. Ms. Voynick fills the vacancy resulting from Sara J. White, a Class I director who stepped down from the Company’s Board of Directors, effective January 5, 2024. In addition, the Company announced that Vance Moore will not stand for reelection to the Company’s Board at Omnicell’s 2024 annual meeting of stockholders (the “2024 annual meeting”) and effective as of the 2024 annual meeting, the size of the Board will be reduced from ten to nine directors.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will present at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023 at 1:00 p.m. ET.

Omnicell, Inc. (Nasdaq: OMCL), a leader in transforming the pharmacy care delivery model, today announced that Kentucky-based Baptist Health has selected Omnicell’s Central Pharmacy Dispensing Service in an effort to address labor challenges and improve clinical and financial outcomes.

Omnicell, Inc. (NASDAQOMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced results for its third quarter ended September 30, 2023.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the third quarter 2023, before market open on Thursday, November 2, 2023. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day.

Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy care delivery model, announced that it will present at the 2023 Wells Fargo Healthcare Conference on Wednesday, September 6, 2023 at 3:00 p.m. ET.

Omnicell, Inc. (NASDAQOMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced results for its second quarter ended June 30, 2023.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the second quarter 2023, after market close on Tuesday, August 1, 2023. The Company will host a conference call and webcast to discuss its financial results at 4:30 p.m. ET that same day.

Omnicell, Inc. (NASDAQOMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced it has increased its number of board seats from 9 to 10, and has appointed Kaushik “Bobby” Ghoshal to fill the newest seat as an independent director of Omnicell’s Board of Directors, effective immediately.

Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced changes to its leadership structure designed to create a more streamlined organization with a continued focus on operational excellence, driving continuous improvements in customer experience and the delivery of Omnicell’s long-term commitments.

Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced that Nchacha E. Etta has been appointed Executive Vice President and Chief Financial Officer of the Company, effective June 1, 2023. Mr. Etta succeeds Peter J. Kuipers, who, as previously announced, will be stepping down from his role as Executive Vice President and Chief Financial Officer. Mr. Kuipers will remain with the Company through July 1, 2023, to help ensure a smooth transition of responsibilities.

Omnicell, Inc. (NASDAQOMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy care delivery model, announced that it will present at the BofA Securities 2023 Healthcare Conference on Thursday, May 11, 2023 at 8:00 a.m. PT.

Omnicell, Inc. (NASDAQOMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced results for its first quarter ended March 31, 2023.

Long Island University and Omnicell, Inc. (Nasdaq: OMCL) (Omnicell), a leading provider of medication management and adherence tools for health systems and pharmacies, announced the opening of the Center for Innovative Medication Management (CIMM), a state-of-the-art laboratory designed to provide an immersive pharmacy technology and analytics experience for LIU pharmacy students. Long Island University is in the top 7% of research institutions in the United States, as designated by the Carnegie Classification.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the first quarter 2023 after market close on Tuesday, May 2, 2023. The Company will host a conference call and webcast to discuss its financial results at 4:30 p.m. ET that same day.

Omnicell, Inc. (NASDAQOMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for fiscal year and fourth quarter ended December 31, 2022.

The first sentence of the second paragraph of the release dated Feb. 15, 2023, has been corrected to replace the dial-in numbers for the earnings call on Tuesday, February 28, 2023.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced that they will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 8:15 a.m. Pacific Time.

Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that it will showcase the Company’s Advanced Services at this year’s American Society of Health-System Pharmacists (ASHP) Midyear 2022 Clinical Meeting and Exhibition, to be held December 5-8, 2022 in Las Vegas.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced its participation in the upcoming investor conference:

Omnicell, Inc. (NASDAQOMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its third quarter ended September 30, 2022 and updated 2022 guidance.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the second quarter 2022, before market on Wednesday, November 2, 2022. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day.

Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell”), a leading provider of medication management and adherence tools for health systems and pharmacies, today announced the launch of Specialty Pharmacy Services, a turnkey offering with dedicated services to set up, operate, and optimize a specialty pharmacy program.

Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leading provider of medication management and adherence tools for health systems and pharmacies, held its 2022 Investor Day today and provided an in-depth overview of the Company’s differentiated strategy and unique business model, as well as its Advanced Services portfolio, ESG strategy, and provided more details on its long-term financial targets.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced its participation in the upcoming investor conference:

Omnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management and adherence tools for health systems and pharmacies, today announced that it will host an Investor Day on September 20, 2022 at 1:00 p.m. Eastern Time.

Omnicell, Inc. (NASDAQOMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its second quarter ended June 30, 2022.

Omnicell, Inc. (Nasdaq :OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the second quarter 2022, after market on Thursday, August 4, 2022. The Company will host a conference call and webcast to discuss its financial results at 1:30 p.m. PT that same day.

Omnicell, Inc. (NASDAQOMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its first quarter ended March 31, 2022.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the first quarter 2022, after market on Thursday, April 28, 2022. The Company will host a conference call and webcast to discuss its financial results at 1:30 p.m. PT that same day.

Omnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management and adherence tools for health systems and pharmacies, today announced the launch of IVX Station. This innovative solution is designed to scale the benefits of leveraging IV robotic technology, making it accessible to the mainstream market.

Omnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management and adherence tools for health systems and pharmacies, today announced that UMC Health System (“UMC”) in Lubbock, Texas, has selected Omnicell’s comprehensive portfolio of Advanced Services solutions to support key pharmacy initiatives, including acute care, outpatient, retail, and 340B program strategies.

Omnicell, Inc. (NASDAQOMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its fourth quarter and fiscal year ended December 31, 2021.

Omnicell, Inc. (NASDAQOMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the fourth quarter and full-year 2021, after market on Monday, February 14, 2022. The Company will host a conference call and webcast to discuss its financial results at 1:30 p.m. PT that same day.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced it has acquired pharmacy software solutions provider MarkeTouch Media, LLC for total aggregate cash consideration of $82 million, subject to customary adjustments. The acquisition is expected to expand the footprint of Omnicell’s EnlivenHealthTM division across the retail pharmacy sector, while enhancing potential growth opportunities in new market segments like specialty pharmacy and pharmacy benefits management.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, has completed the previously announced acquisition of ReCept Holdings, Inc. The addition of ReCept’s specialty pharmacy management services for health systems, provider groups, and federally qualified health centers (FQHCs) expands Omnicell’s Advanced Services portfolio to address the growing and complex specialty pharmacy market.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced it has entered into a definitive agreement with ReCept Holdings, Inc., a leading provider of specialty pharmacy management services for health systems, clinics, and physician groups, to acquire its business for total aggregate cash consideration of $100 million, subject to customary adjustments. The acquisition will broaden Omnicell’s portfolio of capabilities and services to address the significant need to improve access to and care coordination for complex medications.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced its participation in the upcoming investor conferences:

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, and Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition, are collaborating to provide U.S. hospitals and health systems with innovative new pharmacy technology designed to support safety and efficiency in dispensing of controlled substances in patient care areas.

Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that Tucson VA Medical Center has chosen the Company’s Central Pharmacy Dispensing Service (“CPDS”) in an effort to enhance patient safety, improve operational efficiency, and optimize inventory management for its central pharmacy operations.

Omnicell, Inc. (NASDAQOMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its third quarter ended September 30, 2021.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the third quarter of 2021 before the open of the market on Tuesday, November 2, 2021. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day.

Omnicell, Inc. (NASDAQOMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that it has completed the previously announced acquisition of FDS Amplicare. The acquisition adds a comprehensive and complementary suite of SaaS financial management, analytics, and population health solutions to Omnicell’s EnlivenHealth™ division.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced its latest enhancements to the Company’s industry-leading portfolio of medication management solutions. The Summer 2021 Release is designed to deliver greater process efficiency, expand automation to support medication workflows, and provide greater intelligence for workflow optimization. The release also provides greater platform deployment options, offering customers more flexibility and improving time to value for strategic initiatives.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that South Carolina-based Spartanburg Regional Healthcare System, a long-time Omnicell partner, has selected the Company’s industry-leading medication management platform to enhance efficiency, control, and safety across the care continuum.

Omnicell, Inc. (NASDAQOMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its second quarter ended June 30, 2021.

Omnicell, Inc. (NASDAQOMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced it has entered into a definitive agreement with pharmacy software solutions provider FDS Amplicare to acquire its business for total aggregate cash consideration of $177 million, subject to customary adjustments. The acquisition will add a comprehensive and differentiated suite of financial management, analytics, and population health solutions to Omnicell’s EnlivenHealth™ division, broadening offerings that we believe will help pharmacies to measurably improve patient health outcomes while enabling new clinical services and expanding growth and profitability opportunities.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced it has increased its number of board seats from 9 to 10, and has appointed Edward P. Bousa to fill the newest seat of the Company’s Board of Directors, effective immediately. Mr. Bousa will serve as an independent director and as a member of the Board’s Corporate Governance Committee.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the second quarter of 2021 before the open of the market on Thursday, July 29, 2021. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day.

Chartwell Pennsylvania, LP, the nation’s leading health-system based provider of home infusion, specialty pharmacy, and enteral nutrition, has partnered with Omnicell to install their IVX Workflow sterile compounding technology to manage chemotherapy drug product preparations. A leading provider of medication management solutions and adherence tools for health systems and pharmacies, Omnicell’s IVX Workflow solution is designed to enhance safety, ensure dosing accuracy, and facilitate compliance, which will allow Chartwell to lead the way to zero-error medication management.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that Scripps Health has selected the Company’s industry-leading medication management platform to improve pharmacy supply chain management across its San Diego-based network.

Omnicell, Inc. (NASDAQOMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its first quarter ended March 31, 2021.

Omnicell, Inc., (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that its EnlivenHealth™ division is partnering with Twilio, the leading cloud communications and customer engagement platform, to accelerate the creation and launch of breakthrough patient engagement solutions designed to transform the practice and business of retail pharmacy. Studies have shown that better patient engagement and communications produce measurably better patient adherence and health outcomes, leading to increased patient retention, improved quality scores, and higher revenue growth and profitability for pharmacies.1, 2